Tentori, L <br/><br/>
Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.  [electronic resource] 

 -  Current cancer drug targets  Jun 2010 
 - 368-83 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-5576 
<br/><br/><label>Standard No.: </label>10.2174/156800910791208571  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Blotting, Western<br/>Cell Division--drug effects<br/>Cell Line, Tumor<br/>Dacarbazine--analogs & derivatives<br/>Drug Synergism<br/>Enzyme Inhibitors--pharmacology<br/>Flow Cytometry<br/>G2 Phase--drug effects<br/>HeLa Cells<br/>Humans<br/>Melanoma, Experimental--pathology<br/>Methylation<br/>Mice<br/>Netropsin--analogs & derivatives<br/>Poly(ADP-ribose) Polymerase Inhibitors<br/>Poly(ADP-ribose) Polymerases--genetics<br/>Temozolomide